International price regulations in the pharmaceutical sector: A common model to sharing cost and benefits

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 15, Issue 2, 2007, Pages 21-40

  Capri, Stefano ^a   Levaggi, Rosella ^b  

^a CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Bargaining; Drug pricing; Regulated market

Indexed keywords

CONSUMER; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; GOVERNMENT; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; INCOME; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW;

EID: 34249068490     PISSN: 15385698     EISSN: 15385396     Source Type: Journal    
DOI: 10.1300/J371v15n02_03     Document Type: Review

References (24)

1. Achilladelis B., and Antonakis N. (2001). The dynamics of technological innovation: the case of the pharmaceutical industry. Research Policy, 30, 535-588.
2. Berndt E.R. (2002). Pharmaceuticals in the U.S. Health Care: Determinants of Quantity and Price. Journal of Economic Perspective, 16(4), 45-66.
3. Capri S., and Levaggi R. (2002). Pricing policies in a regulated market: The pharmaceutical sector. Drug Information Journal, 36, 453-464.
4. Danzon P.M., and Chao L.W. (2000a). Does regulation drive out competition in pharmaceutical markets? Journal of Law and Economics, 43, 311-357.
5. Danzon P.M., and Towse A. (2003). Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. Journal of Health Care Finance and Economics, 3, 183-205
6. Danzon P.M., and Chao L.W. (2000b). Cross-national price differences for pharmaceuticals: How large, and why? Journal of Health Economics, 19, 159-195.
7. DiMasi J.A., Hansen R.W., and Grabowski H.G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics, 22, 151-185.
8. Drummond M. and McGuire A. (2001). Economic Evaluation in Health Care, Oxford University Press, Oxford.
9. Ess S.M., Schneeweiss S., Szucs T.D. (2003). European healthcare policies for controlling drug expenditure. Pharmacoeconomics, 21(2), 89-103.
10. Garcia Marinoso B., Jelovac I., Olivella P. (2004). Internationally based price regulation and price regulation patterns, paper presented at the V Workshop of Health Economics, York.
11. Gravelle H. (1998). Ex post value reimbursement for pharmaceuticals. Medical Decision Making, 18 suppl, S27-S38.
12. Ioannides-Demos L.L., Ibrahim J.E., McNeil J.J. (2002). Reference-based pricing schemes effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics, 20(9), 577-591.
13. Jacobzone S. (2000). Pharmaceutical policies in OECD: Reconciling social and industrial goals, OECD Labour market and social policy, occasional papers.
14. Jelovac I. (2002). On the relationship between negotiated prices of pharmaceuticals and patients' copayment, paper presented at the III Workshop of Health Economics, Marseille, 8-9 November.
15. Kanavos P., and Reinhardt U. (2003). Reference pricing for drugs: Is it compatible with U.S. health care? Health Affairs, 22(3), 16-30.
16. Lanjouw J.O. (2005). Patents, price controls and access to new drugs: How policy affects global market entry. NBER Working Paper No. 11321, MayLoeb, M. e W.A. Magat (1979) A decentralised method for utility regulation. Journal of Law and Economics, 22, 299-404.
17. Mishan E.J. (1988). Cost-benefit analysis (fourth edition), Unwin Hyman, London.
18. OECD. (2005). OECD Health Data 2005. Paris: OECD.
19. PhRMA. (2005). Pharmaceutical Industry Profile 2005- From laboratory to patient: pathways to biopharmaceutical innovation. Washington: Pharmaceutical Research and Manufacturers of America.
20. Scherer F.M. (1993). Pricing, profits and technological progress in the pharmaceutical Industry. Journal of Economic Perspectives: 97-115.
21. Vernon J.A. (2005). Examining the link between price regulation and pharmaceutical R&D investment. Health Economics, 14, 1-16.
22. World Bank. (2002). World Development Report 2002: Building Institutions for Markets. The world Bank, Washington, DC.
23. Wright D.J. (2004). The drug bargaining game: Pharmaceutical regulation in Australia. Journal of Health Economics, 23, 785-813.
24. Zweifel P., and Breyer F. (1997). Health Economics, Oxford University Press, Oxford.